Want to see GB:VRCI full AI Analyst Report?
VRCI Stock Chart & Stats
0.72 p
0.25 p(4.35%)
At close: 4:00 PM EST
0.72 p
0.25 p(4.35%)
Day’s Range― - ―
52-Week Range0.35 p - 1.25 p
Previous CloseN/A
Volume9.63K
Average Volume (3M)6.85M
Market Cap
£8.58M
Enterprise Value7.37M
Total Cash (Recent Filing)£3.34M
Total Debt (Recent Filing)£197.07K
Price to Earnings (P/E)―
Beta-1.47
Next Earnings
Sep 14, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.01
Shares Outstanding2,287,311,300
10 Day Avg. Volume9,044,876
30 Day Avg. Volume6,845,005
Financial Highlights & Ratios
PEG Ratio0.02
Price to Book (P/B)1.20
Price to Sales (P/S)2.08
P/FCF Ratio-0.93
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)>-0.01
Revenue Forecast (FY)£4.90M
Bulls Say, Bears Say
Bulls Say
Strong Revenue AccelerationSustained, multi-year revenue acceleration signals strengthening product adoption and market penetration in transplant diagnostics. Durable top-line growth provides a foundation for scaling lab partnerships, negotiating payor coverage, and leveraging fixed-cost absorption to improve long-term profitability prospects.
Positive And Growing Gross ProfitPositive gross profit demonstrates that unit economics are viable at present volumes, which is critical for a diagnostics business. As volumes rise, gross margin leverage can enable sustainable margins, fund R&D and commercial expansion, and support transition toward operating profitability over the medium term.
Low Leverage With Positive EquityA relatively low debt burden and positive equity provide financial flexibility and reduce near-term solvency pressure. This conservatism lowers interest obligations and preserves capacity to raise growth capital or execute partnerships without excessive leverage, supporting strategic options over 2-6 months.
Bears Say
Worsening Operating Cash BurnSignificantly increased negative operating and free cash flow is a persistent structural weakness that raises financing risk. Continued cash burn forces reliance on external funding, can dilute shareholders, and constrains the company's ability to invest in commercialization or weather slower adoption periods.
Persistent And Widening Net LossesOngoing, material net losses reduce retained earnings and limit reinvestment capacity. Without durable margin expansion or sustained revenue scale, losses will continue to pressure equity and could necessitate repeated financings, impeding long-term value creation and strategic autonomy.
Declining Asset Base Increases Funding RiskA shrinking asset base reduces collateral and signals resource depletion, making external financing harder or costlier. Combined with cash burn and losses, declining assets heighten the likelihood of dilutive capital raises or constrained growth investment, limiting strategic flexibility over time.
Verici Dx Plc News
VRCI FAQ
What was Verici Dx Plc’s price range in the past 12 months?
Verici Dx Plc lowest share price was 0.35 p and its highest was 1.25 p in the past 12 months.
What is Verici Dx Plc’s market cap?
Verici Dx Plc’s market cap is £8.58M.
When is Verici Dx Plc’s upcoming earnings report date?
Verici Dx Plc’s upcoming earnings report date is Sep 14, 2026 which is in 74 days.
How were Verici Dx Plc’s earnings last quarter?
Verici Dx Plc released its earnings results on Apr 15, 2026. The company reported -0.002 p earnings per share for the quarter, missing the consensus estimate of N/A by -0.002 p.
Is Verici Dx Plc overvalued?
According to Wall Street analysts Verici Dx Plc’s price is currently Overvalued.
Does Verici Dx Plc pay dividends?
Verici Dx Plc does not currently pay dividends.
What is Verici Dx Plc’s EPS estimate?
Verici Dx Plc’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Verici Dx Plc have?
Verici Dx Plc has 2,287,311,300 shares outstanding.
What happened to Verici Dx Plc’s price movement after its last earnings report?
Verici Dx Plc reported an EPS of -0.002 p in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Verici Dx Plc?
Currently, no hedge funds are holding shares in GB:VRCI
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Verici Dx Plc
Verici Dx plc is an immuno-diagnostics company primarily focused on the kidney transplantation sector. The firm specializes in creating both predictive and diagnostic assays for patients who have undergone kidney transplants. Its development pipeline features Clarava, a pre-transplant tool designed to forecast the likelihood of early acute rejection; Tuteva, a post-transplant assessment focusing on acute cellular rejection; and Protega, an innovative liquid biopsy aiming to predict the risk of fibrosis and eventual graft failure. Established in 2020, Verici Dx plc maintains its headquarters in Penarth, United Kingdom.
Technical Analysis
EKF Diagnostics Holdings
―
Genedrive
―
Oxford BioDynamics
―
Renalytix
―
Abingdon Health PLC
―
Options Prices
Currently, No data available
---